Merrill Cuts Pharmaceutical Resources to 'Neutral'

Analyst Gregory Gilbert sees earnings and cash flow upside from the drugmaker's generic Paxil

Merrill Lynch downgraded Pharmaceutical Resources (PRX ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.